Cardiol Therapeutics announced on February 20, 2025, the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science (JACBTS). The article, titled 'Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling,' supports the development of the company's proprietary subcutaneous drug candidate, CRD-38, for heart failure.
The research, conducted by scientists from Tecnológico de Monterrey and the DeBakey Heart and Vascular Center, demonstrated that pharmaceutically manufactured cannabidiol, administered subcutaneously, provides cardioprotection in a preclinical model of heart failure. This protection was observed through improved cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death. The findings suggest a key mode of action for CRD-38 is its ability to sustain cardiomyocytes and preserve mitochondrial function.
Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer, stated that these new data provide important rationale for CRD-38 as a new approach to heart failure treatment. The company plans to incorporate this information into its CRD-38 development program as it completes IND-enabling work to advance the candidate into clinical development. Heart failure remains a leading cause of hospitalization globally, with associated healthcare costs in the United States exceeding $30 billion annually.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.